About Themis BioscienceThemis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications.
Founder and CEO: Erich Tauber
CFO: David A. Maier
Please click here for clinical trial information.
29 articles with Themis Bioscience
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the completion of the acquisition of Themis, a privately-held company focused on vaccines and immune-modulation therapies for infectious diseases and cancer. The U.S. Federal Trade Commission has granted early termination of the waiting period under t
Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur
Merck has largely stayed out of the COVID-19 battle, but exploded into it with three major deals and collaborations today.
ABL applies its expertise in custom manufacturing virus-based therapeutics to accelerate the Institut Pasteur and Themis' coalition COVID-19 vaccine development [11-May-2020] VIENNA , and STRASBOURG, France , May 11, 2020 /PRNewswire/ -- Themis , a clinical-stage biopharmaceutical company focused on immunomodulation therapies for infectious diseases and cancer, and
10/31/2019Companies from across the globe share updates to their businesses and pipelines.
Coalition for Epidemic Preparedness Innovations (CEPI) partnership will support Themis’ development and manufacturing of vaccine candidate
10/3/2019Companies from across the globe share information on their business and pipelines.
European Union’s Horizon 2020 Program Funding Underwrites Second-Generation Zika Vaccine Candidate Development
Themis Raises EUR 40 Million in Series D Financing Round Backed by US/EU Consortium to Support Pivotal Study and Expand Clinical Pipeline
Themis well-funded through completion of Chikungunya Phase 3 program
Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates
Themis Bioscience announced a research collaboration and exclusive license agreement with MSD for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform.
6/6/2019Companies from across the globe share updates on their pipelines and growth strategies.
Funding will support this registration study and rapid global availability of the vaccine against Chikungunya
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.
Themis Bioscience announced that the United States Food and Drug Administration has granted fast track designation to the Company’s lead vaccine candidate for the prevention of Chikungunya, a debilitating disease with global outbreak potential.
Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in The Lancet
MV-CHIK met the primary endpoint, eliciting a potent immune response as measured by induction of neutralizing antibodies against Chikungunya, in all treatment groups
Themis Bioscience Announces Exclusive Licensing Agreement with Max-Planck-Innovation to Develop and Commercialize Oncolytic Virotherapies
Themis to expand measles vector immunomodulation portfolio into oncology indications
The PRIME scheme is designed to provide enhanced regulatory support for the development of medicines that target an unmet medical need.
First major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI’s highest priority infectious diseases.
The purpose of the SAB will be to advise Themis as it continues to develop its pipeline of urgently needed vaccines and immune system activation approaches.
Themis to Present Phase II Interim Results for Chikungunya Vaccine Candidate at ASTMH 2017 Annual Meeting
The data will be presented today for the first time at the Annual Meeting of the ASTMH in Baltimore, MA, USA.